Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Cytodyn, Fibrogen, Immutep, Montreal Heart Institute, Noxopharm, Revimmune.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Atyr, Can-Fite, Eli Lilly, Humanigen, Immunic, Kyowa Kirin, Moderna, Neurorx, Oncoimmune, Opko Health, Opthea, Orpheris, Otsuka, Pluristem, Regeneron, Relief, Sinovac, Solasia, Tychan.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Astellas, Astrazeneca, Bergenbio, Celltrion, CSL Behring, Eli Lilly, Fibrogen, Innovent, Inovio, Junshi, Kiniksa, Neurorx, Novartis, Relief, Sosei, Takeda.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Antisense, Arch Biopartners, Covis, Daiichi Sankyo, Diffusion, Incyte, Mezzion.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Athersys, Biontech, Calcimedica, Cytodyn, Daewoong, Eli Lilly, Enlivex, Hightide, Humanigen, Innovent Biologics, Kiniksa, Mesoblast, Noxopharm, Pfizer, Rising.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Astrazeneca, Atyr, CTI Biopharma, Daiichi Sankyo, Hua Medicine, Immutep, Regeneron, Romark, Sanofi, Theravance.